MS specialists share evidence-based answers on issues from ranging from contraception and conception to breastfeeding, with particular attention to the safety of various disease-modifying therapies.
For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option
A noninferiority trial finds only a small difference in MRI activity in patients 55 or older who stopped DMT after five years of disease stability.
DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy
A major randomized trial comparing escalation of disease-modifying therapy versus early highly effective treatment is being extended from three to six years with an enhanced focus on clinical endpoints.
Switching Disease-Modifying Therapies in Pediatric Multiple Sclerosis: Insights From Real-World Data
For young patients on platform injectable disease-modifying therapy (DMT), switching to an oral or infusion DMT was associated with lower relapse rates compared with switching to another injectable DMT.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Leveraging Real-World Evidence for Treating Multiple Sclerosis (Podcast)
Observational studies have much to add to clinical decision-making in MS care. Our latest podcast features insights from a leader in harnessing real-world data to guide individualized MS therapy.
Breakthrough COVID-19 in Patients With Multiple Sclerosis: Snapshot From One Data Registry
Treatment with an anti-CD20 drug or fingolimod raised risk of breakthrough infection in vaccinated patients, but outcomes remained good.
Managing Multiple Sclerosis During the COVID-19 Pandemic
Stopping or delaying disease-modifying therapy doesn’t appear to lower susceptibility to COVID-19 or the risk of complications from it. But data to date are not definitive, and decisions should be individualized.
Disease-Modifying Therapy for MS: Discontinuing After Age 60 Appears Safe
Disease-modifying therapy for multiple sclerosis is not without risks. Since its benefits may wane as immune function diminishes with age, discontinuation is tempting. A new study gives supportive reassurance.
AAN Releases New Practice Guideline on Disease-Modifying Therapies for Multiple Sclerosis
The 2018 guideline update includes 30 recommendations — 17 on initiating DMT treatment, 10 on switching DMT agents and three on stopping DMT. The lead author shares key takeaways.